Impressive Growth in Cyprus Tourism Revenue: €223.3m in Q1 2024, Surging 11.7% YoY

Revenue from tourism reached an estimated €223.3m in January–March 2024, rising 11.7% compared to €200m in the first quarter of 2023, Cystat said.

Based on the results of its Passengers Survey, in March, revenue from tourism reached €113m, compared to €97.8m in the corresponding month of 2023, recording an increase of 15.5%.

Follow THE FUTURE on LinkedIn, Facebook, Instagram, X and Telegram

The average expenditure per person was €558.88 in March 2024 compared to €530.72 in March 2023 (up 5.3%).

Tourists from the United Kingdom, again Cyprus’ largest tourist market with 31.8% of the total in March, spent on average €73.49 per day, while tourists from Poland, the second largest market with 10.4% of total tourists, spent on average €75.86.

Tourists from Germany, the third largest market with 9.8%, spent on average €98.66 per day, while tourists from Greece with 9% of the market, spent on average €43.37 per day.

Finally, tourists from Israel, the fifth place on the market with 8.2%, spent on average €143.21 per day.

The Future Forbes Realty Global Properties

Cyprus’ MammoCheck Wins Top Honour At NBG Business Seeds Competition

by News Editor

July 14, 2026

Cyprus-based medical technology startup MammoCheck has won first place at the 16th NBG Business Seeds Innovation and Technology Competition, emerging as the overall winner from 344 entries submitted from Greece, Cyprus and other countries.

The annual competition, organised by the National Bank of Greece, announced the results during an awards ceremony in Athens. MammoCheck received the competition’s top distinction along with a €20,000 cash prize.

Follow THE FUTURE on LinkedIn, Facebook, Instagram, X and Telegram

Founded in 2024 as a spin-out from Frederick University, MammoCheck is developing an artificial intelligence-powered Software as a Medical Device (SaMD) platform designed to support breast cancer screening. The solution combines a smartphone application with low-cost thermal cameras to provide an adjunctive screening tool powered by AI.

The company says its technology aims to address a significant gap in breast cancer screening, with hundreds of millions of women worldwide lacking regular access to mammography, including many women under the age of 45 who are not covered by most national screening programmes.

“We are honoured to receive first place among 344 entries from Greece, Cyprus and abroad. This recognition reflects the dedication of our team, our clinical partners and the women who inspire our work every day,”
said Alexandra Dimitriadou, co-founder and CEO of MammoCheck.

MammoCheck is currently conducting a clinical trial across multiple hospital sites as it advances toward FDA 510(k) clearance in the United States and CE marking under the European Union’s Medical Device Regulation (MDR).

The latest award marks another milestone for Cyprus’ growing health technology ecosystem, highlighting the increasing international visibility of locally developed medical innovations.